ACICLOVIR
Sponsors
Friedrich Schiller Universitaet Jena, Beacon Therapeutics (USA) Inc., Fondazione Gimema Franco Mandelli Onlus, Region Uppsala, EMS
Conditions
GENITAL HERPESHerpes ZosterPatients in the intensive care unit on ventilation with pneumonia and detection of herpes simplex virus type 1 (HSV-1) in bronchoalveolar lavage (BAL).Patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration.Relapsing-remitting Multiple SclerosisVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)Viral PneumoniaX-linked retinitis pigmentosa (XLRP)
Phase 2
Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024
RecruitingCTIS2024-511627-34-00
Start: 2024-10-17Target: 31Updated: 2025-12-23
The HIt HArd and hiT early in multiple sclerosis trial – HiHat trial
Not yet recruitingCTIS2024-519700-28-01
Target: 50Updated: 2025-10-22
Phase 3
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
CompletedNCT01281007
Start: 2012-07-31End: 2015-03-31Updated: 2021-04-21
Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster
CompletedNCT01327144
Start: 2012-06-30End: 2017-07-31Updated: 2019-04-17
Effect of acyclovir therapy on the outcome of ventilated patients with lower respiratory tract infection and detection of herpes simplex virus in bronchoalveolar lavage
RecruitingCTIS2023-504322-19-00
Start: 2024-01-10Target: 710Updated: 2025-08-21
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa
WithdrawnCTIS2024-511181-36-00
Target: 5Updated: 2024-09-17